FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof

A composition and compound technology, applied in the field of biomedicine, can solve the problems of low solubility, poor stability, easy isomerization, etc., and achieve the effect of improving solubility and poor stability

Inactive Publication Date: 2016-11-09
ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] According to the characteristics of excellent solubility of FK506/hFKBP12a protein dimer in aqueous solution, the present invention designs and prepares a novel FK506 aqueous solution preparation, and provides a pharmaceutical composition containing FK506 compound/FKBP protein dimer, It is a new type of FK506 medical agent prepared by using drug-protein dimer. The

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof
  • FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof
  • FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] The preparation method of FK506 / hFKBP12a protein dimer aqueous solution is as follows:

[0046] (1) Use an analytical balance to precisely weigh 4 mg of FK506 powder and dissolve it in 0.2 ml of pure DMSO to prepare a DMSO solution of 20 mg / ml (ie about 25 mM) of FK506;

[0047] (2) Dilute the high-purity hFKBP12a protein into a 0.1 mM hFKBP12a protein solution using PBS buffer (osmotic pressure 320 mOsm / L) at pH 7.5;

[0048] (3) Use the hFKBP12a protein solution (50ml) in the above step (2) to slowly dilute the DMSO solution (0.2ml) of FK506 in the step (1), and stir slowly and uniformly to form the FK506 / hFKBP12a protein dimer, thereby 50.2ml of FK506 / hFKBP12a protein dimer aqueous solution was obtained. The molar ratio of FK506 to hFKBP12a protein in the FK506 / hFKBP12a protein dimer aqueous solution is 1:1, and the final concentration of FK506 / hFKBP12a protein dimer is 100 μM. The DMSO solution of 20mg / ml (ie 25mM) of FK506 in step (1) is diluted 250 times with th...

Embodiment 2

[0056] (1) Use an analytical balance to precisely weigh 3.22 mg of FK506 powder and dissolve it in 0.02 ml of absolute ethanol to prepare an ethanol solution of 161 mg / ml (ie about 200 mM) of FK506;

[0057] (2) Dilute the high-purity hFKBP12a protein into a 0.1 mM hFKBP12a protein solution using PBS buffer (osmotic pressure 280 mOsm / L) at pH 7.5;

[0058] (3) Use the hFKBP12a protein solution (40ml) in the above step (2) to slowly dilute the ethanol solution (0.02ml) of FK506 in the step (1), and stir slowly and uniformly to form the FK506 / hFKBP12a protein dimer, thereby 40ml of FK506 / hFKBP12a protein dimer aqueous solution was obtained. The molar ratio of FK506 to hFKBP12a protein in the FK506 / hFKBP12a protein dimer aqueous solution is 1:1, and the final concentration of FK506 / hFKBP12a protein dimer is 100 μM. The ethanol solution of 161mg / ml (i.e. 200mM) of FK506 in step (1) is diluted 2000 times with the 0.1mM hFKBP12a protein solution in step (2), and the organic solvent...

Embodiment 3

[0061] (1) Accurately weigh 3.3 mg of FK506 powder using an analytical balance, and dissolve it in 0.05 ml of pure DMSO to obtain an 80 mM DMSO solution of FK506.

[0062] (2) According to M FK506 :M hFKBP12a蛋白 =1:1.6 ratio, the hFKBP12a protein was dissolved in PBS buffer solution with pH 7.5 to prepare 32ml of 0.2mM hFKBP12a protein solution.

[0063] (3) Mix the solutions obtained in step (1) and step (2) uniformly to form FK506 / hFKBP12a protein dimer, thereby obtaining an aqueous solution of FK506 / hFKBP12a protein dimer (wherein the concentration of FK506 is 0.125mM).

[0064] (4) Then use PBS buffer (pH=7.5, osmotic pressure 260mOsm / L) to dilute 32ml of the FK506 / hFKBP12a protein dimer aqueous solution to 320ml, and then use a 15ml molecular sieve centrifuge tube (centrifuge parameters: 4000g, 40min) The solution was concentrated to 32ml. Thus, an aqueous solution of FK506 / hFKBP12a protein dimer from which the organic solvent DMSO was removed was obtained.

[0065] (5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Osmotic pressureaaaaaaaaaa
Login to view more

Abstract

The invention discloses an FK506 compound/FKBP protein dimer containing pharmaceutical composition and a preparation method thereof. FK506 and hFKBP12a protein in the FK506 compound/FKBP protein dimer containing pharmaceutical composition are combined according to a mass ratio of 1:1, and a PBS buffer solution with pH being 6-8 serves as a solvent. A dimer formed by FK506 and endogenous binding protein hFKBP12a of FK506 can greatly improve solubility of FK506 in a water solution, and accordingly efficacies of an FK506 water solution are enhanced while storage time of the FK506 water solution is prolonged.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to a pharmaceutical composition containing FK506 compound / FKBP protein dimer and a preparation method thereof. Background technique [0002] Tacrolimus, also known as FK506, has the molecular formula C 44 h 69 NO 12 , with a molecular weight of 804, is a fermentation product isolated from Streptomyces tsukubaensis in the soil of Mt. Tsukuba by Fujisawa Pharmaceutical Co., Ltd., Japan. Its chemical structure belongs to 23-membered macrolide antibiotics. As a powerful new immunosuppressant, it mainly suppresses the function of T lymphocytes by inhibiting the release of interleukin-2 (L-2). Its immunosuppressive effect is extremely strong, 100 times stronger than that of similar drug cyclosporine A (CsA). In recent years, as a first-line drug for liver and kidney transplantation, it has been marketed in 14 countries including Japan and the United States. Clinical ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/08A61K47/42A61K31/436A61P37/08A61P27/02
CPCA61K9/08A61K9/0048A61K31/436A61K47/42
Inventor 陈伟蓉陈林林浩添刘奕志
Owner ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap